Trelleborg Expands Testing Capabilities for Pharmaceutical Customers

Trelleborg Medical Solutions has opened its new 490-square-foot laboratory space for analytical testing to support the development of sustained-release and drug-elution technologies.

 

Don Bonitati, Americas Segment Director, Trelleborg Medical Solutions, said: “We are equipped to support customers that need to transfer an existing test method or develop a new one. Not every pharmaceutical company has the capacity or experience to perform its own product release testing. We recognize that each product is unique, so we’ve established methods that fit a product’s specific characteristics, ensuring accurate and reliable results while maintaining cost-effectiveness.”

 

The laboratory is located in Tustin, CA where experts conduct material characterization and oversee products to development. To ensure commercial performance, Current Good Manufacturing Practice (cGMP) requirements are used.

 

“Be it early-stage development, clinical production, manufacturable scalability or market product support, our analytical team can help. We can assist with anything from study design and method development to the execution of tests that provide meaningful data to advance implantable drug delivery systems and combination devices,” Bonitati continued. 

 

At the laboratory, scientists analyze active pharmaceutical ingredients (APIs) which are the substances responsible for the therapeutic action of the drug, excipient polymers, and other materials.